Biophytis Announces Phase 2 Obesity Trial with BIO101

Biophytis SA has unveiled its clinical strategy for a Phase 2 trial of BIO101, targeting muscle wasting in obese patients. This trial includes 164 participants across Brazil and Europe. The focus on these regions aims to balance Brazil's rapid recruitment potential with Europe’s early regulatory engagements.

The global prevalence of obesity affects over 1 billion people, with muscle wastage impacting up to 40% of this population. The related healthcare costs are substantial, highlighting the significance of muscle health in these individuals.

With the strategic involvement of leading clinical centers and a diversified funding model, Biophytis is poised to establish BIO101 as a potential first-in-class therapy in obesity-related muscle decline.